IRD vs NVS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IRD and NVS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IRD and NVS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Opus Genetics develops treatments for eye disease, and it does so along two tracks that have very little to do with each other. The first is a portfolio of AAV gene therapies for inherited retinal diseases, which is where the ticker comes from: IRD is the industry abbreviation for inherited retinal disease. The lead program, OPGx-LCA5, is in a registrational Phase 3 trial for LCA5-associated blindness and carries FDA Rare Pediatric Disease, Orphan Drug and RMAT designations. Behind it sit OPGx-BEST1 for bestrophin-1 related retinal disease, plus earlier programs targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The second track is phentolamine ophthalmic solution 0.75%, which is already FDA-approved and sold by Viatris as RYZUMVI for reversing dilated pupils after an eye exam, and which is under FDA review for a much larger presbyopia indication with a target action date of October 17, 2026. The company was formed when Ocuphire Pharma acquired the private Opus Genetics in late 2024 and took its name, which is why the SEC filer history runs back through Ocuphire and Rexahn.

Full IRD guide

Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. Over the past several years it deliberately reshaped itself into a pure-play innovative-medicines business: it spun off the Alcon eye-care division in 2019 and separated the Sandoz generics and biosimilars unit in 2023, distributing those shares to Novartis holders. What remains is a focused portfolio of patented prescription drugs concentrated in four therapeutic areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic disease. Oncology is its largest contributor, and the company has built a reputation for high core operating margins, reaching roughly 40% in 2025.

Full NVS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• IRD drivers: The presbyopia decision on October 17, 2026; OPGx-LCA5 is in a registrational trial with a defined path.
• NVS drivers: Priority growth brands offsetting the cliff; Focused, high-margin innovative-medicines model.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The trailing numbers do not support the valuation on any conventional measure, so essentially all of the market capitalization rests on events that have not happened yet. For NVS, the dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick IRD if you believe its drivers more; NVS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the IRD and NVS guides.

IRD. No revenue multiple is informative here, because the roughly $9.9 million trailing figure is a development-cost reimbursement that shrinks as programs complete, not a commercial ramp. What the market is pricing instead is the presbyopia royalty stream if the October 2026 sNDA clears, the LCA5 Phase 3 asset, and the newly de-risked BEST1 program, against roughly 83 million shares and a balance sheet that does not force a near-term raise. Sell-side coverage as of early September 2026 clustered around a mean target near $10.71, with Wedbush at $13 and RBC at $9 while explicitly flagging speculative risk, which is a reasonable description of the spread of outcomes.

NVS. Figures are approximate and qualitative, tied to the asOf date; verify live numbers before acting. The near-term picture is a revenue and profit dip as blockbusters lose exclusivity, so the stock is best judged on whether the newer growth brands and pipeline can restore mid-single-digit growth over the medium term rather than on a single trailing quarter.

Headline figures (approximate, September 2026): IRD shows market cap ~$580M after the September 9, 2026 move (~$480M before it), share price ~$7.00, a 52-week high, against a 52-week low of ~$1.32, revenue (ttm) ~$9.9M, almost entirely Viatris collaboration reimbursement, q2 2026 revenue ~$0.8M, down from ~$2.9M in Q2 2025; NVS shows revenue (ttm) Approximately $50 billion in annual net sales; Q1 2026 net sales were about $13.1 billion, down roughly 5% at constant currency on generic erosion, growth drivers Priority brands Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix growing well above 50% at constant currency, offsetting Entresto's decline, margins/profitability High core operating margin, around 40% in 2025; 2026 guidance is for a low single-digit decline in core operating income on generic and R&D pressure, dividend Pays an annual dividend with a long record of increases; yield has recently been roughly 2%, subject to currency and Swiss withholding tax for ADR holders.

IRD and NVS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined IRD and NVS exposure against your real portfolio. It is not an investment adviser.